Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Expression of Mir-181B, Cyld, Cbx-7, Bcl2, and P53 in Osteosarcoma Patients and Correlation With Clinicopathological Factors Publisher Pubmed



Fazli J1 ; Fattah K2 ; Moliani A3 ; Valizadeh A4 ; Bazavar M1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Orthopedic Surgery, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
  2. 2. School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  3. 3. Isfahan Medical Students Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  4. 4. Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran

Source: Chemical Biology and Drug Design Published:2023


Abstract

Osteosarcoma is a common human malignancy with a high mortality rate worldwide. Recent studies have been focused on understanding the involvement of microRNA (miRNAs) in the pathogenesis of osteosarcoma. Therefore, the present study aimed to measure the expression levels of miR-181a, cylindromatosis (CYLD), chromo box homolog 7 (CBX7), B-cell lymphoma 2 (BCL2), and tumor protein p53 in tumor tissue and adjacent normal tissues in patients with osteosarcoma and its relationship with clinicopathological factors. The expression levels of miR-181a, CYLD, CBX7, BCL2, and p53 were measured in 60 patients with osteosarcoma using quantitative real-time polymerase chain reaction. Finally, we compared the relationship between these gene levels and clinicopathological factors in tumor and healthy tissues. Our results showed that the expression levels of miR-181a, BCL2, and p53 were significantly higher in osteosarcoma tissue in comparison with normal tissues (p <.05). On the contrary, CYLD and CBX7 were downregulated in osteosarcoma tumor tissues compared to adjacent healthy tissues (p <.05). In addition, the expression levels of miR-181a in tumor tissues were strongly correlated with patients' age, tumor size, clinical stage, cancer grade, and lymph node metastasis (p <.05). Our findings highlight new insights into understanding the role of miR-181a in the pathogenesis of osteosarcoma. However, further studies are needed to elucidate miRNA as therapeutic targets for osteosarcoma. © 2022 John Wiley & Sons Ltd.
Related Docs
View other Related Docs
1. The Upregulation of Hsa-Mir-181B-1 and Downregulation of Its Target Cyld in the Late-Stage of Tumor Progression of Breast Cancer, Indian Journal of Clinical Biochemistry (2020)
2. Long Noncoding Rna-Mirna-Mrna Axes Multiple Roles in Osteosarcoma, Gene Reports (2021)
3. Dysregulated Expression and Functions of Microrna-330 in Cancers: A Potential Therapeutic Target, Biomedicine and Pharmacotherapy (2022)
4. Emerging Role of Mir-372 and Mir-101A in Head and Neck Squamous Cell Carcinoma, Clinical Laboratory (2020)
5. Mir-370 Expression Analysis in Breast Cancer, Journal of Isfahan Medical School (2015)
6. Expression of Hsa-Mir-204, Runx2, Pparγ, and Bcl2 in Bone Marrow Derived Mesenchymal Stem Cells From, Cell Journal (2017)
7. Microrna-200C Overexpression in Cancer-Associated Fibroblasts Reduces the Invasive Properties of Breast Tumour Cells, Clinical and Translational Discovery (2022)
8. Evaluation of the Effect of Tim-3 Suppression by Mir-498 and Its Effect on Apoptosis and Proliferation Rate of Hl-60 Cell Line, Pathology Research and Practice (2018)
Experts (# of related papers)
View all Related Experts
Mazdak Ganjalikhani Hakemi (4)
Mohammadreza Sharifi (3)
Other Related Docs
9. State of the Art in Microrna As Diagnostic and Therapeutic Biomarkers in Chronic Lymphocytic Leukemia, Journal of Cellular Physiology (2018)
10. Mir-574, Mir-499, Mir-125B, Mir-106A, and Mir-9 Potentially Target Tgfbr-1 and Tgfbr-2 Genes Involving in Inflammatory Response Pathway: Potential Novel Biomarkers for Chronic Lymphocytic Leukemia, Pathology Research and Practice (2022)
11. A Review on Expression and Regulatory Mechanisms of Mir-337-3P in Cancer, Journal of Biomolecular Structure and Dynamics (2024)
12. The Mir-125A-3P Inhibits Tim-3 Expression in Aml Cell Line Hl-60 in Vitro, Indian Journal of Hematology and Blood Transfusion (2017)
13. Inducing Cell Proliferative Prevention in Human Acute Promyelocytic Leukemia by Mir-182 Inhibition Through Modulation of Casp9 Expression, Biomedicine and Pharmacotherapy (2017)
14. Plasma Level of Mir-21 and Mir-451 in Primary and Recurrent Breast Cancer Patients, Breast Cancer: Targets and Therapy (2019)
15. Antiproliferative Effect of Upregulation of Hsa-Let-7C-5P in Human Acute Erythroleukemia Cells, Cytotechnology (2018)
16. Circulating Microrna-192 As a Diagnostic Biomarker in Human Chronic Lymphocytic Leukemia, Cancer Gene Therapy (2016)
17. Singe Nucleotide Polymorphisms in Osteosarcoma: Pathogenic Effect and Prognostic Significance, Experimental and Molecular Pathology (2019)
18. Microrna in Leukemia: Tumor Suppressors and Oncogenes With Prognostic Potential, Journal of Cellular Physiology (2019)
19. Microrna-184 in the Landscape of Human Malignancies: A Review to Roles and Clinical Significance, Cell Death Discovery (2023)
20. Differential Expression Profile of Mir-27B, Mir-29A, and Mir-155 in Chronic Lymphocytic Leukemia and Breast Cancer Patients, Molecular Therapy Oncolytics (2020)
21. Two Lung Development-Related Micrornas, Mir-134 and Mir-187, Are Differentially Expressed in Lung Tumors, Gene (2016)